New Horizons in Cancer Research Conference Draws to a Close

The Fifth AACR New Horizons in Cancer Research (NHiCR) international conference has concluded, and the more than 400 attendees are en route to their home countries, which included Australia, China, Colombia, Germany, Israel, Japan, Korea, Qatar, Singapore, Sweden, and the United States. 

Read More

Conference in China Examines Genomics, Drug Development

Shenzhen is a remarkable place. It serves as a gateway to Hong Kong, and in its short 40-year history has grown to become China’s seventh largest city, with a population of 20 million and some of Mainland China’s tallest buildings. The Fifth AACR New Horizons in Cancer Research (NHiCR) International Conference sessions have attracted more than 350 basic, clinical, and translational researchers and practitioners from throughout China, the Asia-Pacific region, and worldwide.

Read More

AACR Presents New Horizons in Cancer Research in Shenzhen, China

Greetings from Shenzhen, China, where the Fifth AACR New Horizons in Cancer Research (NHiCR) Conference is now underway. The event’s aim is to create and further a global forum for the communication and exchange of knowledge and latest findings in basic, translational, and clinical research and to foster cooperation and network development, leading to a decrease in global cancer incidence and mortality. The conference is co-organized through the collaborative efforts of AACR, Peking University Shenzhen Graduate School, The State Key Laboratory of Chemical Oncogenomics, and Shenzhen Bay Laboratory.

Read More

ICYMI: A Summary of Annual Meeting 2019 Blog Posts

The American Association for Cancer Research (AACR) Annual Meeting 2019 drew more than 21,000 attendees, providing a robust forum to present and discuss the latest breakthroughs in cutting-edge basic, translational, and clinical cancer research. As always, the meeting attracted some of the best minds in research and medicine, representing many facets of cancer care. Researchers, physician-scientists, policymakers, advocates, and industry representatives all played important roles in exchanging information over the course of a dynamic Annual Meeting program.

Read More

AACR Annual Meeting 2019: Past, Present, and Future of CDK4/6-targeted Therapeutics

Therapeutics that target two proteins called cyclin-dependent kinase 4 (CDK4) and CDK6 have revolutionized treatment for breast cancer, Richard S. Finn, MD, told attendees of the Making Science Count for Patients: CDK4/6 special session during the recent AACR Annual Meeting 2019. This session was designed to review the progress made with this class of anticancer therapeutics, starting from basic science through preclinical and clinical development, and to look to what we might expect from these agents in the future.

Read More

AACR Annual Meeting 2019: Leaders Share Highlights and Future Direction

One of the world’s largest cancer research conferences, the AACR Annual Meeting 2019, came to an end with a plenary session titled “AACR Annual Meeting 2019 Highlights: Vision for the Future.” Leaders of the AACR provided an overview of the stellar presentations from the meeting on the topics of prevention, early detection, interception, and the latest breakthroughs in cutting-edge basic, translational, and clinical research.

Read More

AACR Annual Meeting 2019: A Record Year for Clinical Trials Presentations

Over the course of AACR Annual Meeting 2019, there were 213 presentations on incredibly exciting clinical trials. This is a record number of clinical trial presentations for an AACR Annual Meeting. The trials presented covered the continuum of cancer treatment, from surgery, to radiotherapy and chemotherapy, to the two newest pillars of cancer care—molecularly targeted therapy and immunotherapy. The final clinical trials plenary session of the Annual Meeting epitomized this diversity by showcasing clinical trials reporting new ways to combine radiotherapy with other types of treatment, and new advances in immunotherapy and molecularly targeted therapy.

Read More

NIH-AACR Conference Explores Intersection of Cancer, Autoimmunity, and Immunology

Although checkpoint inhibitors and other immunotherapies are remarkably effective for patients with some cancers, demonstrating durable antitumor activity and/or high response rates, they are not risk-free. Reports of immune-related adverse events (therapy-dependent toxicities caused by non-specific activation of the immune system) surfaced early in development for ipilimumab and accompany all approved immunotherapies.

The American Association for Cancer Research (AACR) will join the National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases, and National Institute of Arthritis and Musculoskeletal and Skin Diseases to convene the NIH-AACR Cancer, Autoimmunity, and Immunology Conference on April 15-16, 2019, in the Masur Auditorium on the National Institutes of Health campus in Bethesda, Maryland.

Read More

AACR Annual Meeting 2019: Optimizing PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy

Immune checkpoint inhibitors have become part of the standard of care for more than 14 different cancer types, including melanoma, lung cancer, head and neck cancer, bladder cancer, cervical cancer, liver cancer, stomach cancer, breast cancer, lymphoma, and to treat patients with any type of solid tumor that is microsatellite instability–high or mismatch repair–deficient. In a clinical trial plenary session held April 1 at the AACR Annual Meeting 2019, titled “Optimizing PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy: Dedicated to the Memory of Waun Ki Hong,” cancer researchers updated attendees on the latest advances in the utility of this class of immunotherapeutics, either as monotherapy or in combination with other treatment modalities.

Read More